HCMSG - Hepatitis C Mentor & Support Group, Inc.

  • Home
  • OUR SERVICES
    • Our Services Map
    • The Circle Model >
      • How does the Circle Model Work
      • THE CIRCLE Registration
      • Sites
      • Group and Facilitator Guide
      • Circle Model Data Form
    • HepCTraining
  • RESOURCES
    • Providers >
      • Healthcare Provider TRAINING
    • COVID-19
    • Hep C Facts & Stats
    • Hep C Risks
    • Harm Reduction
    • Medications and Treatments >
      • Patient Assistance Programs
    • Patient Links
    • Reading
    • Blog
  • About Us
    • Our Mission
    • Board of Directors
    • Medical Advisors
    • Support Us
    • Contact Us
  • Home
  • OUR SERVICES
    • Our Services Map
    • The Circle Model >
      • How does the Circle Model Work
      • THE CIRCLE Registration
      • Sites
      • Group and Facilitator Guide
      • Circle Model Data Form
    • HepCTraining
  • RESOURCES
    • Providers >
      • Healthcare Provider TRAINING
    • COVID-19
    • Hep C Facts & Stats
    • Hep C Risks
    • Harm Reduction
    • Medications and Treatments >
      • Patient Assistance Programs
    • Patient Links
    • Reading
    • Blog
  • About Us
    • Our Mission
    • Board of Directors
    • Medical Advisors
    • Support Us
    • Contact Us

Liver Cancer Risk Lingers Even After HCV Eradication

11/23/2021

0 Comments

 
Neil Osterweil
November 17, 2021  MEDSCAPE

Although the risk for liver cancer diminishes for patients with hepatitis C virus (HCV) infections for whom virus is eliminated with direct-acting antiviral (DAA) drugs, these patients are not out of the woods, and those who do not have a sustained viral response (SVR) are at substantially higher risk of developing hepatocellular carcinoma (HCC), results of a large study show.
Among the patients with liver cirrhosis from HCV infections treated at 30 centers in Italy, a large percentage had an SVR after treatment with DAA drugs. Only a small percentage of this group subsequently developed HCC.
In contrast, not having an SVR was associated with a more than sevenfold higher risk for liver cancer, said Loreta A. Kondili, MD, PhD, from the Center for Global Health at the Istituto Superiore di Sanità, in Rome, Italy, during a presentation of the findings at The Liver Meeting 2021: American Association for the Study of Liver Diseases (AASLD), held online.
"Failure to achieve SVR after DAA treatment is strongly associated with the probability of HCC development. Older age, [HCV] genotype 3, and low platelet counts and albumin levels are independent factors of HCC development despite viral eradication," she said.

TO CONTINUE: 
https://www.medscape.com/viewarticle/963101fbclid=IwAR2QowyYfUqAeoNpDsxVI9zPR3xgLvpbNDKcd81IngJOqP7vPLGN-xHZyh8

0 Comments

    Archives

    May 2022
    April 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021

    Categories

    All

    RSS Feed

Privacy Policy
Disclaimer:  Information given by Hepatitis C Mentor and Support Group is not a substitute for advice given by your physician or health care provider.  We do not endorse any doctor, hospital, medical group, or treatment.